Netarsudil and latanoprost combo useful fixed dose option for open-angle glaucoma and IOP: Study
A recent study published in the Graefe’s Archive for Clinical and Experimental Ophthalmology compared the effectiveness and safety of two fixed-dose combination (FDC) ophthalmic solutions for treating open-angle glaucoma (OAG) and ocular hypertension (OHT). This study evaluated the efficacy of the FDC of netarsudil 0.02%/latanoprost 0.005% (NET/LAT; Roclanda®) against bimatoprost 0.03%/timolol maleate 0.5% (BIM/TIM; Ganfort®). Over […]